Residency · Residency · Psychiatry
Sleep Pharmacology: Hypnotics, Melatonin Agonists, and Orexin Antagonists
Introduction
When behavioral interventions such as CBT-I are insufficient or unavailable, pharmacotherapy for insomnia may be appropriate. The landscape of sleep medications has evolved from older sedative-hypnotics with significant abuse potential to newer agents targeting specific neurobiological sleep-wake pathways. This lecture reviews the major pharmacological classes, their mechanisms, efficacy, safety profiles, and clinical considerations.
Neurobiology of Sleep-Wake Regulation
Sleep-Promoting Systems
GABA: the primary inhibitory neurotransmitter; GABA-ergic neurons in the ventrolateral preoptic area (VLPO) promote sleep. Adenosine: accumulates during wakefulness; promotes sleepiness (caffeine is an adenosine receptor antagonist) Melatonin: secreted by the pineal gland in response to darkness; regulates circadian timing of sleep.
Wake-Promoting Systems
Orexin/hypocretin: neuropeptides from the lateral hypothalamus that stabilize wakefulness. Histamine: tuberomammillary nucleus neurons promote arousal. Norepinephrine (locus coeruleus), serotonin (dorsal raphe), dopamine (VTA), and acetylcholine (basal forebrain, pedunculopontine nucleus)
The Flip-Flop Switch Model
Sleep and wake states are maintained by mutually inhibitory systems (VLPO vs. arousal centers) Orexin stabilizes the switch in the wake position; loss of orexin causes narcolepsy.
Benzodiazepines
Mechanism
Positive allosteric modulators at GABA-A receptors; bind the benzodiazepine site and enhance GABA-mediated chloride influx. Non-selective for GABA-A receptor subtypes (alpha-1, alpha-2, alpha-3, alpha-5)
Agents
Temazepam (intermediate-acting): commonly prescribed for insomnia. Triazolam (short-acting): sleep-onset insomnia; risk of anterograde amnesia. Lorazepam, clonazepam: sometimes used off-label.
Clinical Considerations
Effective for short-term use but carry significant risks with chronic use. Tolerance, dependence, and withdrawal with prolonged use. Risk of falls, cognitive impairment, and respiratory depression, particularly in the elderly. Beers Criteria: avoid in older adults. Schedule IV controlled substances. Rebound insomnia upon abrupt discontinuation.
Non-Benzodiazepine Receptor Agonists (Z-Drugs)
Mechanism
Selective for the alpha-1 subunit of the GABA-A receptor (mediating sedation) Theoretically fewer anxiolytic, muscle relaxant, and anticonvulsant effects than benzodiazepines.
Agents
Zolpidem (Ambien): available in immediate-release, extended-release, and sublingual formulations. Zaleplon (Sonata): ultra-short-acting; useful for sleep-onset insomnia and middle-of-night awakenings. Eszopiclone (Lunesta): longer-acting; approved for long-term use without evidence of tolerance over 6 months.
Clinical Considerations
Complex sleep behaviors: sleepwalking, sleep-driving, and sleep-eating reported with zolpidem (FDA boxed warning added 2019) Women metabolize zolpidem more slowly; FDA recommends lower starting doses (5 mg for women) Still carry risk of dependence and next-day impairment, though lower than benzodiazepines. Schedule IV controlled substances.
Melatonin Receptor Agonists
Mechanism
Activate MT1 (sleep onset promotion) and MT2 (circadian rhythm shifting) receptors in the suprachiasmatic nucleus.
Agents
Ramelteon (Rozerem): selective MT1/MT2 agonist; FDA-approved for sleep-onset insomnia. Tasimelteon (Hetlioz): approved for non-24-hour sleep-wake disorder in blind individuals. Exogenous melatonin: available over the counter; variable quality and bioavailability; doses of 0.5-3 mg most physiologic.
Clinical Considerations
No abuse potential; not a scheduled substance. No evidence of rebound insomnia or withdrawal. Modest effect sizes compared to benzodiazepines and Z-drugs. Best suited for circadian rhythm disorders, sleep-onset insomnia, and elderly patients. Avoid in patients on fluvoxamine (CYP1A2 inhibitor markedly increases ramelteon levels)
Dual Orexin Receptor Antagonists (DORAs)
Mechanism
Block the binding of orexin-A and orexin-B to OX1 and OX2 receptors, reducing wake-promoting signaling. Promote sleep by dampening arousal rather than inducing sedation.
Agents
Suvorexant (Belsomra): approved at 10-20 mg; effective for sleep onset and maintenance. Lemborexant (Dayvigo): approved at 5-10 mg; favorable profile for both sleep onset and maintenance. Suvorexant and lemborexant are Schedule IV.
Clinical Considerations
Novel mechanism distinct from GABAergic agents. Lower abuse potential than benzodiazepines and Z-drugs. Most common side effect: next-day somnolence. Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms reported at higher doses (reflecting orexin's role in narcolepsy) Growing evidence for use in elderly patients, including those with mild to moderate dementia. Do not combine with strong CYP3A4 inhibitors.
Comparison of Insomnia Pharmacotherapy Classes
| Class | Examples | Mechanism | Abuse Potential | Best For | Major Risks |
|---|---|---|---|---|---|
| Benzodiazepines | Temazepam, triazolam | GABA-A (non-selective) | High (Schedule IV) | Short-term insomnia | Dependence, falls, cognitive impairment |
| Z-drugs | Zolpidem, zaleplon, eszopiclone | GABA-A (alpha-1 selective) | Moderate (Schedule IV) | Sleep onset (zaleplon); onset + maintenance (eszopiclone) | Complex sleep behaviors, next-day impairment |
| Melatonin agonists | Ramelteon, tasimelteon | MT1/MT2 agonist | None (unscheduled) | Circadian disorders; elderly; sleep onset | Modest efficacy; avoid with fluvoxamine |
| DORAs | Suvorexant, lemborexant | OX1/OX2 antagonist | Low (Schedule IV) | Sleep onset + maintenance; elderly/dementia | Next-day somnolence; sleep paralysis (rare) |
| Low-dose doxepin | Silenor (3-6 mg) | H1 antagonist | None | Sleep maintenance in elderly | Minimal at low doses |
| Trazodone | Desyrel (25-100 mg) | 5-HT2A/H1 antagonist | None | Off-label; comorbid depression | Orthostatic hypotension; priapism (rare) |
Other Sedating Agents Used for Insomnia
Trazodone
Low-dose (25-100 mg) is the most commonly prescribed off-label agent for insomnia. Mechanism: 5-HT2A antagonism and H1 histamine blockade. No controlled substance scheduling; no abuse potential. Risks: orthostatic hypotension, priapism (rare), next-day sedation.
Doxepin (Silenor)
Low-dose (3-6 mg) selectively antagonizes H1 receptors; FDA-approved for sleep maintenance insomnia. At low doses, minimal anticholinergic or cardiac effects. Well-studied in elderly populations.
Gabapentin and Pregabalin
Enhance slow-wave sleep; useful when insomnia is comorbid with pain, anxiety, or alcohol use disorder. Not first-line for primary insomnia.
Hydroxyzine and Diphenhydramine
H1 antihistamines; commonly used over the counter. Rapid tolerance development; significant anticholinergic effects. Avoid in elderly patients due to cognitive impairment and fall risk.
Key Clinical Pearls
CBT-I should be offered before or alongside pharmacotherapy for chronic insomnia. Z-drugs are not inherently safer than benzodiazepines; complex sleep behaviors are a serious concern. DORAs represent a mechanistically novel class with lower abuse potential and are increasingly preferred. Melatonin receptor agonists are safest for elderly patients but have modest efficacy. Always discuss sleep medication risks, including next-day impairment, dependence, and complex sleep behaviors, as part of informed consent.
References
- Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349.
- Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136-148.
- Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014;28(9):799-816.
- Schroeck JL, Ford J, Conway EL, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38(11):2340-2372.